Lumi Research

1. Novartis Pharmaceuticals Corporation $1,310,143 10 payments
2. Mirati Therapeutics, Inc. $1,056,505 28 payments
3. Amgen Inc. $374,839 8 payments
4. AstraZeneca UK Limited $271,293 3 payments
5. Genmab U.S., Inc. $269,840 16 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $221,965 14 payments
7. BeiGene, Ltd. $120,960 2 payments
8. GlaxoSmithKline, LLC. $69,841 28 payments
9. Genentech, Inc. $52,900 8 payments
10. F. Hoffmann-La Roche AG $15,605 4 payments

1. A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $966,190 4 payments
2. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $952,563 27 payments
3. P3 3L + Vectibix vs Pi choice CRC CB 300 $276,532 4 payments
4. A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY $271,293 3 payments
5. A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. $269,840 16 payments
6. A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected Tki in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $227,148 3 payments
7. A Phase 1/2 Open-Label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Tak-573 As A Single Agent in Patients With Refractory Multiple Myeloma $144,403 11 payments
8. A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia $120,960 2 payments
9. Ph2 Multi Center Open Label Randomized Study in CML CP Patients Previously Treated With Imatinib and Not Achieved DMR Asciminib Imatinib VS Continued Imatinib VS Switch to Nilotinib $116,804 3 payments
10. Phase 1/2 Study of MRTX849 in Patients with Cancer Having a KRAS G12C Mutation KRYSTAL-1 $103,941 1 payment

1. Patient care $250,645 15 payments
2. Non-patient care $105,633 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.